BIT Capital GmbH Grows Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

BIT Capital GmbH lifted its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 8.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 73,990 shares of the biotechnology company's stock after buying an additional 5,569 shares during the period. Ascendis Pharma A/S makes up 0.8% of BIT Capital GmbH's portfolio, making the stock its 21st biggest position. BIT Capital GmbH owned about 0.12% of Ascendis Pharma A/S worth $10,186,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Legato Capital Management LLC lifted its holdings in Ascendis Pharma A/S by 7.5% in the fourth quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company's stock valued at $264,000 after acquiring an additional 134 shares during the period. Jones Financial Companies Lllp boosted its holdings in shares of Ascendis Pharma A/S by 394.0% in the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock worth $34,000 after buying an additional 197 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Ascendis Pharma A/S during the third quarter valued at approximately $30,000. GAMMA Investing LLC raised its position in Ascendis Pharma A/S by 58.0% in the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock worth $80,000 after acquiring an additional 214 shares during the period. Finally, Blue Trust Inc. raised its holdings in Ascendis Pharma A/S by 415.2% during the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock valued at $56,000 after acquiring an additional 328 shares during the period.

Remove Ads

Ascendis Pharma A/S Price Performance

Ascendis Pharma A/S stock traded down $3.04 during mid-day trading on Monday, reaching $151.64. 186,352 shares of the company traded hands, compared to its average volume of 471,285. The firm's fifty day moving average is $144.16 and its two-hundred day moving average is $137.34. The company has a market capitalization of $9.20 billion, a price-to-earnings ratio of -21.36 and a beta of 0.62. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $169.37.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($1.32) by $0.64. As a group, equities research analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on ASND. Evercore ISI increased their price objective on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an "outperform" rating in a report on Tuesday, February 18th. The Goldman Sachs Group raised their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. Cantor Fitzgerald boosted their target price on Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an "overweight" rating in a research report on Tuesday, February 25th. UBS Group started coverage on Ascendis Pharma A/S in a research note on Tuesday, January 7th. They set a "buy" rating and a $196.00 price target for the company. Finally, JPMorgan Chase & Co. upped their price objective on Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an "overweight" rating in a research report on Tuesday, March 18th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $204.64.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.